STOCK TITAN

FSI ANNOUNCES THE APPOINTMENT OF DR. KIM REID AS DIRECTOR

(Neutral)
(Positive)
Tags

Flexible Solutions International (NYSE-American: FSI) announced that Dr. Kim Reid has been appointed as a director and member of the audit committee, serving until the next Annual Meeting. The company also reported the resignation of long-serving director and former audit committee chair, John Bientjes, and the appointment of David Fynn as the new audit committee chair.

Dr. Reid is a process development scientist and Postdoctoral Fellow at the Ottawa Hospital Research Institute, leading technology transfer for mRNA-LNP cancer-vaccine production into GMP bio-manufacturing. Her background spans biomanufacturing, molecular biology, health research, GMP procedures, and leadership, and she has extensive academic qualifications and publication experience.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

FSI's historical news reactions included both +9.16% and -3.94% 24-hour moves, showing varied respon...
Analysis

FSI's historical news reactions included both +9.16% and -3.94% 24-hour moves, showing varied responses to company announcements. The director change adds governance context; the effective S-3 shelf remains a relevant risk factor to watch.

Key Figures

Director service tenure: nearly thirty years Food and nutrition market entry: 2022 Canadian fighter-pilot milestone: third woman +1 more
4 metrics
Director service tenure nearly thirty years John Bientjes' service as director
Food and nutrition market entry 2022 Company entered the food and nutrition markets
Canadian fighter-pilot milestone third woman Dr. Reid's position among women to fly fighter aircraft in Canada
Combat-mission qualification milestone first woman Operational qualification for both NORAD and NATO combat missions

Historical Context

5 past events · Latest: Aug 14 (Negative)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Aug 14 Second-quarter earnings Negative +6.9% Revenue declined and the company reported a net loss versus prior-year income.
Jul 20 Second-quarter revenue Negative -10.8% Preliminary revenue declined 35% year over year amid weaker sales.
May 15 First-quarter earnings Neutral -3.9% Revenue and operating cash flow improved while the company remained unprofitable.
Apr 21 First-quarter revenue Positive +9.2% First-quarter revenue increased 11% year over year, supported by new sales.
Apr 15 Full-year earnings Negative +5.9% Net income declined sharply despite completed facility investments and debt repayment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

FSI's historical reactions were mixed, with positive and negative responses across earnings and revenue announcements.

Key Terms

mRNA-LNP, GMP, bioreactors, fill-and-finish
4 terms
mRNA-LNP medical
"bring mRNA-LNP cancer-vaccine production from academia into scaled GMP bio-manufacturing"
mRNA-LNP is a medical delivery technology that packages messenger RNA (mRNA) inside tiny lipid nanoparticles (LNPs) so the genetic instructions can enter cells safely and produce a protein. It matters to investors because it is the key method used in many mRNA vaccines and therapies, so advances, manufacturing capacity, regulatory outcomes, supply-chain constraints, or intellectual property around mRNA-LNPs can affect the commercial prospects and valuation of biotech companies; think of LNPs as specialized shipping containers for fragile biological cargo.
GMP regulatory
"She has experience in upstream and downstream process development, assay development, quality control and assurance, GMP"
Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.
bioreactors technical
"GMP clean-room procedures, bioreactors, filtration, chromatography and fill-and-finish"
A bioreactor is a controlled vessel where living cells or microorganisms are grown to produce medicines, vaccines, enzymes, or other biological materials; think of it as an industrial kitchen that provides the right ingredients, temperature and conditions so the ‘recipe’ can be made reliably. Investors care because a company’s bioreactor capacity, efficiency and regulatory compliance determine how much product can be made, the cost per dose or unit, and how quickly a developer can scale revenue or respond to demand and safety issues.
fill-and-finish technical
"filtration, chromatography and fill-and-finish"
The stage of pharmaceutical or vaccine manufacturing where bulk drug substance is transferred into individual final containers (vials, syringes, or bags), sealed, labeled, and prepared for distribution. It matters to investors because delays, capacity limits, or quality problems in fill-and-finish can slow product availability and revenue, much like a factory bottleneck that prevents finished goods from reaching store shelves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

TABER, ALBERTA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE-AMERICAN: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. In addition, FSI is increasing its presense in the food and nutrition supplement manufacturing markets. Today the Company wishes to announce the appointment of Dr. Kim Reid as director and audit committee member.

"The Board of Directors wishes to announce the resignation of Director John Bientjes after nearly thirty years of service. We are sad to lose his official advice but, John will remain as a friend and confidant of the Company. Mr. Bientjes also served as Audit Committee Chair; Mr. David Fynn, who has been on the Audit Committee for many years, has accepted the Audit Committee Chair position.

We are also pleased to announce the appointment of Dr. Kim Reid as Director and Audit Committee member, to serve until the next Annual Meeting. Dr. Reid is a process development scientist with a background in bio-manufacturing, molecular biology, health research, and operational leadership. She is currently a Postdoctoral Fellow in the John C. Bell Laboratory at the Ottawa Hospital Research Institute, where she leads a technology transfer team to bring mRNA-LNP cancer-vaccine production from academia into scaled GMP bio-manufacturing. She has experience in upstream and downstream process development, assay development, quality control and assurance, GMP clean-room procedures, bioreactors, filtration, chromatography and fill-and-finish. She holds a PhD in Biology from the University of Ottawa, an MSc in Experimental Pathology and Laboratory Medicine from UBC, an Advanced Biotechnology Diploma from Algonquin College, a BSc in Biology, and a combined BSc in Physics and Physical Oceanography. She has completed specialized training in GMP and mRNA/mRNA-LNP biomanufacturing.

Kim’s research has been published in peer-reviewed journals including Scientific Reports, Journal of Biological Chemistry, and Endocrinology, and her work as a freelance systematic reviewer has involved leading multidisciplinary teams in the examination of clinical and health-economics evidence for international clients. Her current professional engagement includes founding and leading the Expert Talk Series for the Society for RNA Therapeutics. Early in her career, Kim served with the Royal Canadian Air Force as an officer and fighter pilot, flying the CT-114 Tutor, CF-5 Freedom Fighter and CF-18 Hornet with 441 Tactical Fighter Squadron. She was the third woman to fly fighter aircraft in Canada and the first woman to become operationally qualified for both NORAD and NATO combat missions. Her experience will allow her to contribute to scientific and board discussions, particularly where technology, innovation, risk, regulated environments, evidence-based decision-making and organizational leadership intersect.

We are excited to welcome Dr. Reid and feel sure that she will add depth and new skills to the Board.

Once again, we would like to thank John personally for all his years of service and friendship."

About Flexible Solutions International
Flexible Solutions International, Inc. (www.flexiblesolutions.com), based in Taber, Alberta, is an environmental technology company. The Company’s NanoChem Solutions Inc. subsidiary specializes in biodegradable, water-soluble products utilizing thermal polyaspartate (TPA) biopolymers. TPA beta-proteins are manufactured from the common biological amino acid, L-aspartic and have wide usage including scale inhibitors, detergent ingredients, water treatment and crop enhancement. Along with TPA, this division started producing other crop enhancement products as well. In 2022, the Company entered the food and nutrition markets by obtaining FDA food grade approval for the Peru IL plant. The other divisions manufacture energy and water conservation products for drinking water, agriculture, industrial markets and swimming pools throughout the world.

Safe Harbor Provision
The Private Securities Litigation Reform Act of 1995 provides a "Safe Harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward looking statement with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Flexible Solutions International
6001 54th Ave, Taber, Alberta, CANADA T1G 1X4
                                        

Company Contacts
Jason Bloom
Toll Free: 800.661.3560
Fax: 403.223.2905
Email: info@flexiblesolutions.com

To find out more information about Flexible Solutions and our products please visit www.flexiblesolutions.com

If you have received this news release by mistake or if you would like to be removed from our update list please reply to: info@flexiblesolutions.com


FAQ

What board changes did Flexible Solutions International (FSI) announce on August 31, 2026?

Flexible Solutions International announced that Dr. Kim Reid joined the board and audit committee, while long-serving director John Bientjes resigned. According to Flexible Solutions, David Fynn, an existing audit committee member, has become audit committee chair following Bientjes’ departure after nearly thirty years of service.

Who is Dr. Kim Reid, the newly appointed director of Flexible Solutions International (FSI)?

Dr. Kim Reid is a process development scientist with expertise in bio-manufacturing, molecular biology, and health research. According to Flexible Solutions, she holds a PhD in Biology and multiple advanced degrees, and leads mRNA-LNP cancer-vaccine technology transfer at the Ottawa Hospital Research Institute.

What will be Dr. Kim Reid’s role on the Flexible Solutions International (FSI) board?

Dr. Kim Reid has been appointed as a director and audit committee member, serving until the next Annual Meeting. According to Flexible Solutions, her experience in technology, regulated environments, risk, and evidence-based decision-making is expected to support both scientific and board-level discussions.

Who is the new audit committee chair at Flexible Solutions International (FSI) in 2026?

The new audit committee chair is David Fynn, a long-time audit committee member. According to Flexible Solutions, he assumed the chair role following the resignation of director and former audit committee chair, John Bientjes, who served the company for nearly thirty years.

What is the professional background of FSI director Dr. Kim Reid in mRNA and GMP biomanufacturing?

Dr. Kim Reid leads a technology transfer team bringing mRNA-LNP cancer-vaccine production into scaled GMP bio-manufacturing. According to Flexible Solutions, she has specialized training in GMP and mRNA/mRNA-LNP biomanufacturing, with experience in process development, quality systems, bioreactors, and fill-and-finish operations.

What industries and products does Flexible Solutions International (NYSE-American: FSI) focus on?

Flexible Solutions develops biodegradable polymers for oil extraction, detergents, water treatment, and crop enhancement, plus water and energy conservation technologies. According to Flexible Solutions, its NanoChem subsidiary produces thermal polyaspartate products, and the company entered food and nutrition markets in 2022 with FDA food grade approval.